Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years. - Wikidata - awgldk - TriplyDB

Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.

Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.

http://www.wikidata.org/entity/Q37118381

about

Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule.Primary Immunization of Human Papillomavirus Vaccine in the Pediatric Population: What Is the Verdict Now?Current status and future prospects for human papillomavirus vaccines.Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized Trial.Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline.Antibody responses among adolescent females receiving two or three quadrivalent human papillomavirus vaccine doses at standard and prolonged intervals.Vaccination programs for older adults in an era of demographic change.

P2860

Q33724422-A86D74F6-0CCA-4BFB-BC30-39A3DAD05B82 Q39306396-891F84E6-D600-4D73-A76B-1886E4952422 Q40056541-771CF9D6-61F0-44D6-AB61-78DEF6910B59 Q40168801-17AD3963-E590-4384-A1AB-7A8A0FA31A81 Q47111040-AC613467-CD09-4BE2-9402-B88BC090E1A5 Q47561555-1BDFFC2A-8C8A-4312-8D36-A2A42BD027E5 Q54963907-E115FABF-7251-4233-B384-131D71266694

P2860

Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.

http://www.wikidata.org/entity/Q37118381

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 03 February 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Randomized Open Trial Comparin ...... men in Women Aged 15-25 Years.

@en

Randomized Open Trial Comparin ...... men in Women Aged 15-25 Years.

@nl

type

label

Randomized Open Trial Comparin ...... men in Women Aged 15-25 Years.

@en

Randomized Open Trial Comparin ...... men in Women Aged 15-25 Years.

@nl

prefLabel

Randomized Open Trial Comparin ...... men in Women Aged 15-25 Years.

@en

Randomized Open Trial Comparin ...... men in Women Aged 15-25 Years.

@nl

P1433

Q37118381-F8FB25B0-13EE-46F5-A559-11561E5CC3CF

P1476

Q37118381-92B150A1-55A3-4297-9C1B-A3BB4AEA7977

P2093

Q37118381-0610413F-6589-4FE9-AD05-DD617704FB76

Q37118381-08BB419C-B2E2-47FC-9F88-61696E0E5B66

Q37118381-11B99C22-03DA-4315-9504-98FBFD20D2C0

Q37118381-21339987-8690-4028-B9E9-CE4550B864A0

Q37118381-25837398-30F9-45FB-A774-E96B5F3563F1

Q37118381-291A411A-6B44-4609-A578-44CE4832808B

Q37118381-384047A5-C810-4DAF-B81B-F874A12053D8

Q37118381-689875F9-69F2-4BBA-88B2-E929C4CFFA3D

Q37118381-6C658D64-DE58-4FC8-875E-52E74985C5CB

Q37118381-6FBFEFFC-5866-448C-865A-2FBA1E41E4D5

P2860

Q37118381-013CC039-2480-4FCB-8EBC-B2D9B51B8FFB

Q37118381-0460B38C-871D-429E-AC69-FA3D98837029

Q37118381-08D9482E-FF55-498D-9D2B-075896BD5253

Q37118381-122395EF-8568-4414-BCFB-08D0483E8F82

Q37118381-15C90D0C-8FC9-4721-A06F-FD0F351B3A26

Q37118381-1A3F85F1-4EC7-44F9-AE04-B63FC9AD2B20

Q37118381-1C05243B-15C8-482E-B6E6-7DFEC4205F5A

Q37118381-26A9D8FA-A7B3-4D9B-9C1D-868B9D463AB6

Q37118381-291B6849-FDF4-4CE8-A976-5201DEB565B7

Q37118381-2DA38B68-EF12-4B6A-BB8B-B676E1FD6C28

P304

Q37118381-22842EF0-5769-4317-9078-DA29D57CA681

P31

Q37118381-47A18E72-1C5D-46D3-9AC1-61817C4046DB

P356

Q37118381-EC81D3C0-5541-40BE-BBD4-742E6430F6C9

P407

Q37118381-008CA30D-4E0A-4AC0-9ED0-F9B913C495F4

P433

Q37118381-18A0BFA7-4B74-4A72-81CD-94F225C4DB4D

P478

Q37118381-6A8ED147-1D9F-4632-8BD1-B9513261FE66

P50

Q37118381-5310B477-6BA3-4547-A9E3-53F3F6210F86

Q37118381-AD563185-531D-4E22-BF97-8B5A73A82DA1

Q37118381-C0889DF4-6461-4197-8912-62B2C8AE0E2C

Q37118381-D30C59CC-D36F-40A9-A4B5-1260A90A887C

Q37118381-F91CC30A-4B8D-4BD8-AC06-F01789982ED2

P577

Q37118381-9741BDB5-1479-406B-8DE0-0D0E5043B7D0

P5875

Q37118381-1DFDDD09-B2D1-4B93-AECB-EAA21A9AF9F8

P698

Q37118381-86D17F18-1677-40FC-9673-55AEA1CD9E91

P932

Q37118381-ADBB9F11-417D-4074-B9B4-C0D2B40D3949

P356

P1433

The Journal of Infectious Diseases

P1476

Randomized Open Trial Comparin ...... imen in Women Aged 15-25 Years

@en

P2093

Benoit De Muynck

http://www.w3.org/2001/XMLSchema#string

Carlo Giaquinto

http://www.w3.org/2001/XMLSchema#string

Cheng-Hsun Chiu

http://www.w3.org/2001/XMLSchema#string

Damien Friel

http://www.w3.org/2001/XMLSchema#string

Dominique Descamps

http://www.w3.org/2001/XMLSchema#string

Florence Thomas

http://www.w3.org/2001/XMLSchema#string

Louise Frenette

http://www.w3.org/2001/XMLSchema#string

Marjan Hezareh

http://www.w3.org/2001/XMLSchema#string

Michael Horn

http://www.w3.org/2001/XMLSchema#string

Paolo Durando

http://www.w3.org/2001/XMLSchema#string

P2860

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.

Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.

Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.

Human papillomavirus and cervical cancer.

P304

525-536

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INFDIS/JIW036

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

214

http://www.w3.org/2001/XMLSchema#string

P50

Susanna Esposito

Shelly A McNeil

P577

2016-02-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

293011275

http://www.w3.org/2001/XMLSchema#string

P698

26908726

http://www.w3.org/2001/XMLSchema#string

P932

4957434

http://www.w3.org/2001/XMLSchema#string